0001789192 false Q1 --12-31 0001789192 2022-01-01 2022-03-31 0001789192 2022-03-31 0001789192 2021-12-31 0001789192 2021-01-01 2021-03-31 0001789192 us-gaap:CommonStockMember 2021-12-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001789192 SVFD:ForeignCurrencyTranslationAdjustmentsMember 2021-12-31 0001789192 us-gaap:RetainedEarningsMember 2021-12-31 0001789192 SVFD:StockholdersEquityMember 2021-12-31 0001789192 us-gaap:NoncontrollingInterestMember 2021-12-31 0001789192 us-gaap:CommonStockMember 2020-12-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001789192 SVFD:ForeignCurrencyTranslationAdjustmentsMember 2020-12-31 0001789192 us-gaap:RetainedEarningsMember 2020-12-31 0001789192 SVFD:StockholdersEquityMember 2020-12-31 0001789192 us-gaap:NoncontrollingInterestMember 2020-12-31 0001789192 2020-12-31 0001789192 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001789192 SVFD:ForeignCurrencyTranslationAdjustmentsMember 2022-01-01 2022-03-31 0001789192 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001789192 SVFD:StockholdersEquityMember 2022-01-01 2022-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001789192 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001789192 SVFD:ForeignCurrencyTranslationAdjustmentsMember 2021-01-01 2021-03-31 0001789192 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001789192 SVFD:StockholdersEquityMember 2021-01-01 2021-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001789192 us-gaap:CommonStockMember 2022-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001789192 SVFD:ForeignCurrencyTranslationAdjustmentsMember 2022-03-31 0001789192 us-gaap:RetainedEarningsMember 2022-03-31 0001789192 SVFD:StockholdersEquityMember 2022-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2022-03-31 0001789192 us-gaap:CommonStockMember 2021-03-31 0001789192 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001789192 SVFD:ForeignCurrencyTranslationAdjustmentsMember 2021-03-31 0001789192 us-gaap:RetainedEarningsMember 2021-03-31 0001789192 SVFD:StockholdersEquityMember 2021-03-31 0001789192 us-gaap:NoncontrollingInterestMember 2021-03-31 0001789192 2021-03-31 0001789192 2009-04-27 0001789192 2021-05-08 2021-05-13 0001789192 SVFD:ConsultingAgreementsMember SVFD:Mr.JoachimFuchsMember 2022-01-28 2022-01-31 0001789192 SVFD:Mr.JoachimFuchsMember 2022-03-23 2022-03-24 0001789192 SVFD:LetterAgreementMember SVFD:FebruaryTwoThousandTwentyTwoWarrantMember 2022-02-01 0001789192 SVFD:LetterAgreementMember SVFD:FebruaryTwoThousandTwentyTwoWarrantMember 2022-01-28 2022-02-01 0001789192 SVFD:LetterAgreementMember SVFD:FebruaryTwoThousandTwentyTwoWarrantMember 2022-01-01 2022-03-31 0001789192 SVFD:LetterAgreementMember SVFD:FebruaryTwoThousandTwentyTwoWarrantMember 2022-03-31 0001789192 SVFD:InvestorRelationAgreementMember 2022-03-09 2022-03-10 0001789192 SVFD:InvestorRelationAgreementMember 2022-01-01 2022-03-31 0001789192 SVFD:ConsultingAgreementsMember 2022-01-25 2022-01-27 0001789192 SVFD:ConsultingAgreementsMember 2022-01-01 2022-03-31 0001789192 2021-02-22 2021-02-23 0001789192 us-gaap:GeneralAndAdministrativeExpenseMember SVFD:DirectorsCompensationMember 2022-01-01 2022-03-31 0001789192 us-gaap:GeneralAndAdministrativeExpenseMember SVFD:DirectorsCompensationMember 2021-01-01 2021-03-31 0001789192 us-gaap:GeneralAndAdministrativeExpenseMember SVFD:SalariesAndFeesToOfficersMember 2022-01-01 2022-03-31 0001789192 us-gaap:GeneralAndAdministrativeExpenseMember SVFD:SalariesAndFeesToOfficersMember 2021-01-01 2021-03-31 0001789192 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001789192 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001789192 us-gaap:ResearchAndDevelopmentExpenseMember SVFD:SalariesAndFeesToOfficersMember 2022-01-01 2022-03-31 0001789192 us-gaap:ResearchAndDevelopmentExpenseMember SVFD:SalariesAndFeesToOfficersMember 2021-01-01 2021-03-31 0001789192 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001789192 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001789192 us-gaap:CostOfSalesMember SVFD:SalariesAndFeesToOfficersMember 2022-01-01 2022-03-31 0001789192 us-gaap:CostOfSalesMember SVFD:SalariesAndFeesToOfficersMember 2021-01-01 2021-03-31 0001789192 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001789192 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001789192 us-gaap:SellingAndMarketingExpenseMember SVFD:SalariesAndFeesToOfficersMember 2022-01-01 2022-03-31 0001789192 us-gaap:SellingAndMarketingExpenseMember SVFD:SalariesAndFeesToOfficersMember 2021-01-01 2021-03-31 0001789192 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001789192 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001789192 SVFD:RelatedPartiesAndOfficersMember 2022-03-31 0001789192 SVFD:RelatedPartiesAndOfficersMember 2021-03-31 0001789192 srt:ChiefFinancialOfficerMember SVFD:ConsultingAgreementsMember 2021-06-21 2021-06-23 0001789192 srt:ChiefFinancialOfficerMember SVFD:ConsultingAgreementsMember 2021-11-13 2021-11-14 0001789192 srt:ChiefFinancialOfficerMember srt:MinimumMember 2022-01-15 2022-01-18 0001789192 srt:ChiefFinancialOfficerMember srt:MaximumMember 2022-01-15 2022-01-18 0001789192 country:IL 2022-01-01 2022-03-31 0001789192 country:IL 2021-01-01 2021-03-31 0001789192 country:US 2022-01-01 2022-03-31 0001789192 country:US 2021-01-01 2021-03-31 0001789192 srt:CentralAmericaMember 2022-01-01 2022-03-31 0001789192 srt:CentralAmericaMember 2021-01-01 2021-03-31 0001789192 SVFD:CustomerAMember 2022-01-01 2022-03-31 0001789192 SVFD:CustomerAMember 2021-01-01 2021-03-31 0001789192 SVFD:CustomerBMember 2022-01-01 2022-03-31 0001789192 SVFD:CustomerBMember 2021-01-01 2021-03-31 0001789192 SVFD:CustomerCMember 2022-01-01 2022-03-31 0001789192 SVFD:CustomerCMember 2021-01-01 2021-03-31 0001789192 SVFD:CustomerMember 2022-01-01 2022-03-31 0001789192 SVFD:CustomerMember 2021-01-01 2021-03-31 0001789192 country:IL 2022-03-31 0001789192 country:IL 2021-03-31 0001789192 country:US 2022-03-31 0001789192 country:US 2021-03-31 0001789192 us-gaap:SubsequentEventMember SVFD:InvestorRelationAgreementMember 2022-04-01 2022-04-01 0001789192 us-gaap:SubsequentEventMember 2022-04-01 0001789192 us-gaap:SubsequentEventMember SVFD:VestUponLapsOfTwelveMonthsMember 2022-04-01 0001789192 us-gaap:SubsequentEventMember SVFD:VestUponLapsOfEighteenMonthsMember 2022-04-01 2022-04-01 0001789192 us-gaap:SubsequentEventMember SVFD:VestUponLapsOfEighteenMonthsMember 2022-04-01 0001789192 us-gaap:SubsequentEventMember SVFD:VestUponLapsOfTwentyFourMonthsMember 2022-04-01 0001789192 us-gaap:SubsequentEventMember 2022-04-16 2022-04-17 0001789192 us-gaap:SubsequentEventMember 2022-04-17 0001789192 us-gaap:SubsequentEventMember SVFD:ConsultingAgreementsMember SVFD:JuneFifteenTwoThousandTwentyOneMember 2022-05-01 2022-05-02 0001789192 SVFD:ConsultingAgreementsMember us-gaap:SubsequentEventMember 2022-05-01 2022-05-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS iso4217:CAD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                    To                    

 

Commission File No. 000-56100

 

SAVE FOODS, INC.
(Exact name of registrant as specified in its charter)

 

Delaware   26-4684680
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

 730 NW 107 Avenue    
Miami, Florida   33172
(Address of Principal Executive Offices)   (Zip Code)

 

(347) 468 9583
(Registrant’s telephone number, including area code)

 

n/a

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, Par value $0.0001 per share   SVFD   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of March 31, 2022, the registrant had 2,842,036 shares of common stock, par value $0.0001 (the “Common Stock”) issued and outstanding.

 

As used in this Quarterly Report and unless otherwise indicated, the terms “Save Foods,” “we,” “us,” “our,” or “our Company” refer to Save Foods, Inc. and Save Foods Ltd., the 98.48% owned subsidiary of Save Foods, Inc. Unless otherwise specified, all dollar amounts are expressed in United States dollars.

 

 

 

 

 

 

Save Foods, Inc.

 

Quarterly Report on Form 10-Q

 

TABLE OF CONTENTS

 

  Page
Cautionary Note Regarding Forward-Looking Statements 3
   
PART I - FINANCIAL INFORMATION  
     
Item 1. Condensed Consolidated Interim Financial Statements (unaudited) 5
     
  Condensed Consolidated Interim Balance Sheets (unaudited) 6
     
  Condensed Consolidated Interim Statements of Comprehensive Loss (unaudited) 7
     
  Condensed Consolidated Interim Statements of Stockholders’ Equity (unaudited) 8
     
  Condensed Consolidated Interim Statements of Cash Flows (unaudited) 9
     
  Notes to Condensed Consolidated Interim Financial Statements 10
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 20
     
Item 4. Control and Procedures 20
     
PART II - OTHER INFORMATION  
     
Item 1A. Risk Factors 21
     
Item 6. Exhibits 22
     
SIGNATURES 23

 

2

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

 

our expectations regarding our short and long-term capital requirements;
   
our history of operating losses and expectation to incur additional losses in the future;
   
our ability to raise additional capital to meet our liquidity needs;
   
because of our limited operating history, we may not be able to successfully operate our business or execute our business plan;
   
our products and technology requiring additional trials;
   
commercial success of our new generation products, as well as any future products, depends upon the degree of market acceptance by the packing house community as well as by other prospect markets and industries
   
our ability to comply with the continued listing standards of the Nasdaq Capital Market;
   
sales of our products;
   
the size and growth of our product market;
   
our marketing plans;
   
our activity in the civilian market;
   
our ability to obtain market acceptance of our environmentally friendly solutions for fruits and vegetables;
   
our inability to respond effectively to technological changes in our industry, which could reduce the demand for our products;
   
our ability to satisfy or maintain compliance in the U.S. (including the U.S. Food and Drug Administration, the United States Environmental Protection Agency and the California Department of Pesticide Regulation), and international regulatory requirements and obtain required approvals for sales or exports of our products;
   
our ability to achieve regulatory approvals and registration in the United States and abroad (Mexico, Israel, Spain and Italy), which might take longer than expected;
   
significant competition from other companies looking to develop or acquire new alternative environmentally friendly solutions for the treatment of fruits and vegetables, and other edible matter;
   
our reliance on a limited number of suppliers to produce certain key components of our products;
   
our plans to continue to invest in research and development;
   
our ability to establish and maintain strategic partnerships with third parties, including for the distribution of products;

 

3

 

 

our ability to establish sales, marketing and distribution capabilities or enter into successful relationships with third parties to perform these services;
   
our reliance on rapidly establishing global distributorship network in order to effectively market our products;
   
results of our early tests may not be indicative of results in future tests and we cannot assure you that any planned or future tests will lead to results sufficient for the necessary regulatory approvals;
   
inherent dangers in production and transportation of hydrogen peroxide and highly concentrated organic acids could cause disruptions and could expose us to potentially significant losses, costs or other liabilities;
   
our ability to attract and retain sufficient, qualified personnel;
   
our ability to obtain or maintain patents or other appropriate protection for the intellectual property;
   
our ability to grow both domestically and internationally;
   
our ability to adequately support future growth;
   
potential product liability or intellectual property infringement claims;
   
our business and operations may be affected by climate change conditions, which could materially harm our financial results;
   
risks relating to portfolio concentration;
   
risks relating to international expansion of our business and operations;
   
the effect of COVID-19 on our business; and
   
information with respect to any other plans and strategies for our business.

 

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2021 (filed on March 31, 2022) (“2021 Annual Report”) entitled “Risk Factors” as well as in our other public filings.

 

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

 

On February 23, 2021, we implemented a one-for-seven reverse stock split of our Common Stock pursuant to which holders of our Common Stock received one share of our Common Stock for every seven shares of Common Stock held. Unless the context expressly dictates otherwise, all references to share and per share amounts referred to herein reflect the reverse stock split.

 

4

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Interim Financial Statements (unaudited).

 

SAVE FOODS, INC.

 

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

AS OF MARCH 31, 2022

IN U.S. DOLLARS

 

TABLE OF CONTENTS

 

  Page
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED):  
   
Condensed Consolidated Interim Balance Sheets (unaudited) 6
Condensed Consolidated Interim Statements of Comprehensive Loss (unaudited) 7
Condensed Consolidated Interim Statements of Stockholders’ Equity (unaudited) 8
Condensed Consolidated Interim Statements of Cash Flows (unaudited) 9
Notes to Condensed Consolidated Interim Financial Statements 10 - 15

 

5

 

 

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

(U.S. dollars except share and per share data)

 

     March 31, 2022     December 31, 2021 
   March 31, 2022   December 31, 2021 
Assets          
Current Assets          
Cash and cash equivalents   5,644,466    6,750,938 
Restricted cash   55,416    56,674 
Accounts receivable, net   201,853    172,630 
Inventories   26,568    22,603 
Other current assets   276,028    226,252 
Total Current assets   6,204,331    7,229,097 
           
Right-of-use asset arising from operating lease   168,244    129,613 
           
Property and equipment, net   111,169    100,944 
           
Funds in respect of employee rights upon retirement   136,103    137,625 
Total assets   6,619,847    7,597,279 
           
Liabilities and Shareholders’ Equity          
Current Liabilities          
Short-term loan from banking institutions   6,197    8,390 
Accounts payable   586,703    539,360 
Other liabilities   395,754    383,554 
Total current liabilities   988,654    931,304 
Operating lease liabilities   102,754    87,287 
          
Liability for employee rights upon retirement   164,042    166,077 
           
Total liabilities   1,255,450    1,184,668 
           
Stockholders’ Equity          
Common Stock $ 0.0001 par value per share (“Common Stock”):
495,000,000 shares authorized as of March 31, 2022 and December 31, 2021; issued and outstanding 2,842,036 and 2,806,536 shares as of March 31, 2022 and December 31, 2021, respectively.
   285    281 
Preferred Stock $ 0.0001 par value per share (“Preferred Stock”):
5,000,000 shares authorized as of March 31, 2022 and December 31, 2021; issued and outstanding 0 shares as of March 31, 2022 and December 31, 2021.
   -    - 
Additional paid-in capital   23,898,284    23,607,503 
Foreign currency translation adjustments   (26,275)   (26,275)
Accumulated deficit   (18,427,977)   (17,098,227)
Total   5,444,317    6,483,282 
Non-controlling interests   (79,920)   (70,671)
Total stockholders’ equity   5,364,397    6,412,611 
Total liabilities and stockholders’ equity   6,619,847    7,597,279 

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

6

 

 

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(U.S. dollars except share and per share data)

 

     2022     2021 
   Three months ended March 31 
   2022   2021 
         
Revenues from sales of products   87,630    123,074 
Cost of sales   (41,849)   (2,933)
Gross profit (loss)   45,781   120,141 
Research and development expenses   (209,362)   (69,791)
Selling and marketing expenses   (178,136)   (44,258)
General and administrative expenses   (1,003,957)   (252,971)
Operating loss   (1,345,674)   (246,879)
Financing income (expenses), net   5,904    (247,416)
Net loss   (1,339,770)   (494,295)
Less: net loss attributable to non-controlling interests   10,020    1,893 
Net loss attributable to the Company’s stockholders’ equity   (1,329,750)   (492,402)
           
Loss per share (basic and diluted)   (0.47)   (0.31)
           
Basic and diluted weighted average number of shares of Common Stock outstanding   2,819,253    1,606,765 

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

7

 

 

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(U.S. dollars, except share and per share data)

 

   Number of shares (*)     Amount     Additional paid-in capital     Foreign currency translation adjustments     Accumulated deficit     Total
Company’s stockholders’ equity
     Non-
controlling interests
     Total
stockholders’ deficit
 
   Number of shares (*)   Amount   Additional paid-in capital   Foreign currency translation adjustments   Accumulated deficit   Total
Company’s stockholders’ equity
   Non-
controlling interests
   Total
stockholders’ deficit
 
                                 
BALANCE AT DECEMBER 31, 2021   2,806,536    281    23,607,503    (26,275)   (17,098,227)   6,483,282    (70,671)   6,412,611 
                                         
Issuance of shares to employees and services providers   35,500    4    

279,139

    -    -    279,143    591    279,734 
Share based compensation to employees and directors   

-

    

-

    

11,642

    -    -    11,642    

180

    11,822 
Comprehensive loss for the period   -    -    -    -    (1,329,750)   (1,329,750)   (10,020)   (1,339,770)
BALANCE AT MARCH 31, 2022   2,842,036    285    23,898,284    (26,275)   (18,427,977)   5,444,317    (79,920)   5,364,397 

 

   Number of shares   Amount   Additional paid-in capital   Accumulated other comprehensive income (loss)   Accumulated deficit   Total
Company’s stockholders’ equity
   Non-
controlling interests
   Total
stockholders’ deficit
 
                                 
BALANCE AT DECEMBER 31, 2020   1,606,765    161    11,867,585    (26,275)   (12,277,647)   (436,176)   (29,277)   (465,453)
                                         
Share based compensation to employees and directors   -    -    83,605    -    -    83,605    895    84,500 
Comprehensive loss for the period   -    -    -    -    (492,402)   (492,402)   (1,893)   (494,295)
BALANCE AT MARCH 31, 2021   1,606,765    161    11,951,190    (26,275)   (12,770,049)   (844,973)   (30,275)   (875,248)

 

(*) See note 3(5)

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

 

8

 

 

SAVE FOODS, INC.

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(U.S. dollars except share and per share data)

 

     2022     2021 
   Three months ended March 31, 
   2022   2021 
     
CASH FLOWS FROM OPERATING ACTIVITIES:          
Loss for the period   (1,339,770)   (494,295)
Adjustments required to reconcile net loss for the period to net cash used in operating activities:          
Depreciation and amortization   7,638    

4,821

 
Decrease in liability for employee rights upon retirement   (2,035)   (5,635)
Issuance of shares to employees and services providers   182,094    - 
Share based compensation to employees and directors   

11,822

    

84,500

 
Expenses on convertible loans   -    251,696 
Interest expenses on loans   (174)   - 
Operating lease ROU asset and liability, net   

(3,779

)   

(29

)
Increase in accounts receivable   (29,223)   (10,561)
Decrease (increase) in inventory   (3,965)   377 
Decrease (increase) in other current assets   47,863    (5,167)
Increase in accounts payable   49,247    37,268 
Increase (decrease) in other accounts payable   

(7,181

)   52,477 
Net cash used in operating activities   (1,087,463)   (84,548)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   (17,864)   - 
Increase in funds in respect of employee rights upon retirement   1,522    4,375 
Net cash provided by (used in) investing activities   (16,342)   4,375 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from convertible loans   -    274,000 
Repayments of long-term loans from banking institutions   (2,019)   (1,975)
Increase in prepaid issuance expenses   -    (64,680)
Net cash provided by (used in) financing activities   (2,019)   

207,345

 
Effect of exchange rate changes on cash and cash equivalents   (1,906)   - 
           
INCREASE (DECREASE) IN CASH , CASH EQUIVALENTS AND RESTRICTED CASH   (1,107,730)   127,172 
           
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR   6,807,612    242,900 
           
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD   5,699,882    370,072 
           
Supplemental disclosure of cash flow information:          
Non cash transactions:          
Issuance of shares for future services   97,640    - 
Initial recognition of operating lease right-of-use assets   56,671    - 
Initial recognition of operating lease liability   56,671    - 

 

The accompanying notes are an integral part of the condensed consolidated interim financial statements

 

9

 

 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

 

NOTE 1 - GENERAL

 

Save Foods, Inc. (the “Company”) was incorporated on April 1, 2009, under the laws of the State of Delaware. On April 27, 2009, the Company acquired from its stockholders 98.48% of the issued and outstanding shares of Save Foods Ltd., including preferred and Common Stock. Save Foods Ltd. was incorporated in 2004 and commenced its operations in 2005. Save Foods Ltd. develops, produces, and focuses on delivering innovative solutions for the food industry aimed at improving food safety and shelf life of fresh produce. The Company and Save Foods Ltd. (collectively, the “Group”).

 

On May 13, 2021, the Company completed an underwritten public offering of 1,090,909 shares of its Common Stock for net proceeds of $10,457,862. Commencing on May 14, 2021, Company’s common stock was listed on the Nasdaq Capital under the symbol “SVFD”.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Effects of the spread of the coronavirus

 

The COVID-19 pandemic continues to create business and economic uncertainty and volatility in the global markets. Many countries around the world are experiencing further outbreaks of the pandemic, following which governments are once again imposing various restrictions. At the same time, there is a recovery trend in the volume of economic activity around the world that leads on one hand, to significant demand for certain products and services and on the other hand, disruptions to worldwide supply chain routes and some raw materials. The Group continues to take measures to ensure the health and safety of its employees, suppliers, other business partners and the communities in which it operates in order to ensure, among others, the operation level, the proper functioning of its facilities and to minimize the pandemic’s potential impact on its business. Manufacturing continues at the Group’s sites without interruptions. However, there is still a difficulty in assessing the future impacts of the pandemic on the Group’s operations, inter alia, in light of the uncertainty of its duration, the extent of its intensity and effects on global supply chains and global markets, and additional countermeasures that may be taken by governments and central banks.

 

Principles of Consolidation

 

The consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include the Company and its majority-owned subsidiary. All inter-company balances and transactions have been eliminated.

 

10

 

 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (continue)

 

Use of Estimates

 

The preparation of unaudited condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to share based compensation.

 

NOTE 3 – COMMON STOCK

 

  1. On January 31, 2022, following the Board of Directors of Save Foods Ltd.’s appointment of Mr. Joachim Fuchs as the Chairman of the Board of Directors of Save Foods Ltd, the Board of Directors of the Company (the “Board”) approved the nomination and his consulting agreement. Based on the consulting agreement Mr. Joachim Fuchs is entitled to a monthly fee of NIS5,000 (approximately $1,600) and subject to the approval of the Board, 9,000 shares of common stock and in addition, subject to the terms of the equity incentive plan to be adopted by the Company, options to purchase 1.5% of the Company’s’ outstanding capital stock of which (1) 0.5% of such options shall have an exercise price of $1 and shall be vested in 4 equal quarters during the 12 months period commencing the Effective Date (January 1, 2022), (2) 0.5% of such options shall have an exercise price of $1.25 and shall be vested in 4 equal quarters during the 12 months period following the 12 month anniversary of the Effective Date, (3) 0.5% of such options shall have an exercise price of $1.5 and shall be vested in 4 equal quarters during the 12 months period following the 24 month anniversary of the Effective Date. On March 24, 2022 the Company issued to Mr. Joachim Fuchs 9,000 shares of common stock. The Company determined the value of the shares at $38,790.
     
  2. On February 1, 2022, the Company entered into a Letter Agreement with a consultant according to which the Consultant will provide the Company with public relations, branding and other services as detailed in the Letter Agreement. As consideration for the services, the Company will issue the Consultant, a warrant to purchase up to an aggregate of 77,400 shares of Common Stock of the Company, at an exercise price of $0.05 each (the “February 2022 Warrant”). The February 2022 Warrant will be issuable in five equal tranches, 15,480 warrant shares upon signing of the agreement or the approval of the agreement by the Board, whichever is later and four additional quarterly installments ending in February 2023. In addition, the Company has provided the Consultant anti-dilution rights if at any time after both the (a) the approval of the agreement and (b) the Company having exceeded 3,000,000 shares of common stock. In such event the Consultant shall receive for no consideration additional securities necessary to maintain a fully-diluted ownership percentage (as defined in the Letter Agreement). In addition, the consultant is entitled to convert the February 2022 Warrant into cash, except for the portion of the February 2022 Warrant issuable upon signing of the agreement, upon providing the Company with advance notice of at least 45 days prior to each exercise date, an amount not to exceed 33% of the Warrant Shares due to vest, based on the share price of the Company less the exercise price, with a maximum cash conversion amount of $20,000 for each tranche.

 

The Company determined the value of the cash liability at $13,333 which was recorded as general and administrative expenses in the period of three months ended March 31, 2022.

 

11

 

 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

 

NOTE 3 – COMMON STOCK (continue)

 

The fair value of the February 2022 Warrant was determined based on the Company’s share price as of the date of the agreement using the Black-Scholes pricing model, assuming a risk-free rate of 1.35%, a volatility factor of 78%, dividend yields of 0% and an expected life of 0.75 years and was calculated at $332,859 and net of the cash liability at $319,526.

 

During the three months ended March 31, 2022, the Company recorded $42,143 as share based compensation expenses in respect of the above agreement.

 

  3. On March 10, 2022, the Company entered into an Investor Relations Agreement (the “March IR Agreement”) with a consultant for a period of 12 months. According to the March IR Agreement, the Company will pay the Consultant for his services a monthly fee of $11,000 and in addition, 14,000 shares of Common Stock of the Company, upon execution of the March IR Agreement. The shares were issued on March 10, 2022. The Company determined the value of the shares at $103,600. During the period of three months ended March 31, 2022, the Company recorded share based compensation expenses of $5,961 and the remaining was recorded as prepaid expenses under other current assets.
     
  4. On January 27, 2022, the Company issued 12,500 shares under its October 1, 2021, consulting agreement. During the three months ended March 31, 2022, the Company recorded share based compensation expenses of $95,200 in respect of the above agreement.
     
  5. On February 23, 2021, the Company amended its Certificate of Incorporation to effect a 7 to 1 reverse stock split of the Company’s outstanding Common Stock. All share, stock option and per share information in these consolidated financial statements have been presented to reflect the stock split.

 

NOTE 4 – STOCK OPTIONS

 

The following table presents the Company’s stock option activity for employees and directors of the Company for the three months ended March 31, 2022:

   Number of Options  

Weighted Average

Exercise Price

 
Outstanding at December 31, 2021   192,576    3.38 
Granted   -    - 
Exercised   -    - 
Forfeited or expired   -    - 
Outstanding at March 31,2022   192,576    3.38 
Number of options exercisable at March 31, 2022   183,385    3.38 

 

The aggregate intrinsic value of the awards outstanding as of March 31, 2022 is $455,696. These amounts represent the total intrinsic value, based on the Company’s stock price of $5.75 as of March 31, 2022, less the weighted exercise price. This represents the potential amount received by the option holders had all option holders exercised their options as of that date.

 

Costs incurred in respect of stock-based compensation for employees and directors, for the three months ended March 31, 2022 and 2021 were $11,822 and $84,500, respectively

 

12

 

 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

 

NOTE 5 – RELATED PARTIES

 

A. Transactions and balances with related parties

 

     2022     2021 
   Three months ended March 31, 
   2022   2021 
         
General and administrative expenses:          
Directors compensation   60,533    63,402 
Salaries and fees to officers   173,779    106,161 
General and administrative expenses net   (*) 234,312    (*) 169,563 
           
(*) of which share based compensation   7,925    57,440 
           
Research and development expenses:          
Salaries and fees to officers   (*) 49,063    - 
           
(*) of which share based compensation   1,949    - 
           
Cost of sales:          
Salaries and fees to officers   (*) 17,012    - 
           
(*) of which share based compensation   1,169    - 
           
Selling and marketing expenses:          
Salaries and fees to officers   (*) 76,833    - 
           
(*) of which share based compensation   779    - 

 

B. Balances with related parties and officers:

 

Other current assets   8,308    - 
           
Other accounts payables   118,362    485,611 

 

C. Other information:

 

  1. On June 23, 2021 the Board of Directors of the Company approved the compensation of its Chief Financial Officer (“CFO”), according to which the CFO shall be entitled to a monthly fee of $8,000 and reimbursement of expenses of $500 per month. In addition, the CFO shall receive a one-time grant of options to purchase shares of the Company representing 1.5% of the Company’s outstanding share capital as of the date of the approval. The terms of the grant have not yet been determined. On November 14, 2021, the Board of Directors of the Company approved the increase of the CFO’s monthly fee to $11,500, effective October 1, 2021. On January 16, 2022, the outgoing Chief Financial Officer of the Company, Ms. Vered Raz-Avayo, tendered her resignation to the Board in connection with her role as the Company’s Chief Financial Officer, which resignation will enter into effect on January 31, 2022. Ms. Raz-Avayo’s resignation was due to personal reasons and there were no disagreements between her and the Company or the Board.

 

13

 

 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

 

NOTE 5 – RELATED PARTIES (continue)

 

  2. On January 18, 2022, the Board resolved to appoint Mr. Omri Kanterovich, the Company’s then financial controller, as the Company’s interim Chief Financial Officer, VP of Finance, Treasurer and Secretary, which appointments entered into effect on January 31, 2022. In connection with Mr. Kanterovich’s new positions with the Company, the Board resolved to increase his monthly base salary from NIS 18,000 (approximately $5,800) to NIS 25,000 (approximately $8,000). No additional changes were made to Mr. Kanterovich’s compensation. On April 18, 2022, Mr. Omri Kanterovich tendered his resignation as the Interim Chief Financial Officer, VP of Finance, Treasurer and Secretary of the Company (see also note 7 below).

 

NOTE 6 – GEOGRAPHIC AREAS AND MAJOR CUSTOMERS

 

A. Information on sales by geographic distribution:

 

The Company has one operating segment. Sales are attributed to geographic distribution based on the location of the customer.

 

     2022     2021 
   Three months ended March 31, 
   2022   2021 
         
Israel   11,213    - 
United States   35,948    84,674 
Central-South America   40,469    38,400 
Revenues from sales of products   87,630    123,074 

 

B. Sales to single customers exceeding 10% of sales (US$):

 

     2022     2021 
   Three months ended March 31, 
   2022   2021 
         
Customer A   40,469    38,400 
Customer B   35,948    84,674 
Customer C   11,213    - 
Revenues from sales of products   87,630    123,074 

 

C. Information on Long-Lived Assets - Property, Plant and Equipment and ROU assets by geographic areas:

 

The following table presents the locations of the Company’s long-lived assets as of March 31, 2022 and 2021:

 

     2022     2021 
   As of March 31, 
   2022   2021 
         
Israel   249,306    61,004 
United States   30,107    - 
Property, Plant and Equipment and ROU assets   279,413    61,004 

 

14

 

 

SAVE FOODS, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (unaudited)

 

NOTE 7 – SUBSEQUENT EVENTS

 

  1. On April 1, 2022, the Company entered into an Investor Relations Agreement (the “April IR Agreement”) with a Consultant for a period of 90 days. According to the April IR Agreement, the Company will pay the Consultant for his services a monthly fee of $15,000 and in addition, 12,000 shares of Common Stock of the Company, upon execution of the April IR Agreement. The shares were issued on May 2, 2022.

 

In addition, the Company will issue warrants to purchase 60,000 shares of Common Stock of the Company, of which (a) 20,000 warrants shall vest upon the lapse of 12 months with an exercise price of $8.00, (b) 20,000 warrants shall vest upon the lapse of 18 months with an exercise price of $9.50, and (c) 20,000 warrants shall vest upon the lapse of 24 months with an exercise price of $11.

 

  2. On April 17, 2022, the Board resolved to appoint Ms. Lital Barda, the Company’s current financial controller, as the Company’s CFO, Treasurer and Secretary, which appointment entered into effect on April 18, 2022. In connection with Ms. Barda’s appointment as the Company’s CFO, Treasurer and Secretary, the Board resolved to approve the following terms of compensation, effective immediately upon the effectiveness of Ms. Barda’s appointment: (a) a monthly base salary of NIS 25,000 and (b) a grant of options to purchase such number of shares of the Company’s common stock, par value $0.0001 per share, as shall be agreed upon between Ms. Barda and the Board on a future date, and which shall be in accordance with the terms of the Company’s future equity incentive plan.
     
  3. On May 2, 2022, the Company issued 600 shares to a consultant under its June 15, 2021 consulting agreement. In addition, on May 2, 2022, the Company issued 12,500 shares to a consultant under its October 1, 2021 consulting agreement (see also note 3 above).

 

15

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated interim financial statements (unaudited) and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our 2021 Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements”. You should review the “Risk Factors” section of our 2021 Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Furthermore, certain disclosures and references made herein apply to Save Foods Ltd., the subsidiary of Save Foods, Inc. The primary business activities and operations discussed herein are performed by Save Foods Ltd., whereas Save Foods, Inc. operates as a holding company and is the Registrant for purposes of this Quarterly Report on Form 10-Q.

 

We develop eco-friendly “green” solutions for the food industry. Our solutions are developed to improve the food safety and shelf life of fresh produce. We do this by controlling human and plant pathogens, thereby reducing spoilage, and in turn, reducing food loss.

 

Our products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of oxidizing agent-based sanitizers and fungicides at low concentrations. Our green products are capable of cleaning, sanitizing and controlling pathogens on fresh produce with the goal of making them safer for human consumption and extending their shelf life by reducing their decay. One of the main advantages of our products is that our active ingredients do not leave any toxicological residues on the fresh produce we treat. In contrary, by forming a temporary protective shield around the fresh produce we treat, our products make it difficult for pathogens to develop and potentially provide protection which also reduces cross-contamination.

 

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “SVFD.”

 

Results of Operations

 

Components of Results of Operation

 

Revenues and Cost of Revenues

 

Our total revenue consists of products and our cost of revenues consists of cost of products.

 

The following table discloses the breakdown of revenues and costs of revenues:

 

   Three Months Ended March 31 
   2022   2021 
Revenues from sale of products  $87,630   $123,074 
Cost of sales   (41,849)   (2,933)
Gross profit  $(45,781)  $120,141 

 

Operating Expenses

 

Our operating expenses consist of three components — research and development expenses, selling and marketing expenses and general and administrative expenses.

 

16

 

 

Research and Development Expenses

 

Our research and development expenses consist primarily of salaries and related personnel expenses, laboratory and field tests, professional fees and other related research and development expenses.

 

   Three Months Ended March 31 
   2022   2021 
Salaries and related expenses  $114,815   $2,086 
Share based compensation   1,948    17,916 
Professional fees   24,302    31,014 
Laboratory and field tests   40,995    6,261 
Depreciation   17,790    6,766 
Other expenses   9,512    5,748 
Total  $209,362   $69,791 

 

We expect that our research and development expenses will increase as we continue to develop our products and services, field trials and recruit additional research and development employees.

 

Selling and Marketing Expenses

 

Selling and marketing expenses consist primarily of salaries and related expenses, professional fees and other expenses.

 

   Three Months Ended March 31 
   2022   2021 
Salaries and related expenses  $82,260   $778 
Share based compensation   779    462 
Professional fees   55,621    - 
Commissions   5,466    4,800 
Transport and storage   7,818    5,313 
Other expenses   26,192    32,905 
Total  $178,136   $44,258 

 

We expect that our selling and marketing expenses will increase as we continue to increase our selling and marketing efforts including commercial validation pilots and recruit additional employees or contractor to support our selling and marketing efforts in our targeted geographical areas.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of professional services, share based compensation, insurance and other non-personnel related expenses.

 

   Three Months Ended March 31 
   2022   2021 
Professional services  $552,696   $163,954 
Share based compensation   190,019    65,429 
Salaries and related expenses   90,779    - 
Insurance   135,875    18,908 
Other expenses   34,588    4,680 
Total  $1,003,957   $252,971 

 

17

 

 

Three months ended March 31, 2022 compared to three months ended March 31, 2021

 

Revenues.

 

Revenues for the three months ended March 31, 2022 were $87,630, compared to $123,074 during the three months ended March 31, 2021. The decrease is mainly a result of a decrease in sales due to weather conditions which caused a reduction in citrus production.

 

We do not have backlogs or firm commitments from our customers for our products. Our sales might deteriorate if we fail to achieve commercial success or obtain regulatory approval of any of our products.

 

Cost of Sales

 

Cost of sales consists primarily of salaries, materials, transportation and overhead costs of manufacturing our products. Cost of sales for the three months ended March 31, 2022 were $41,849, compared to $2,933 for the three months ended March 31, 2021. The increase is mainly a result of the increase in salaries and related expenses.

 

Gross Profit

 

Gross profit for the three months ended March 31, 2022 was $45,781, compared to a gross profit of $120,141 for the three months ended March 31, 2021. The decrease is mainly a result of the decrease in revenues and increase in cost of sales, as detailed above.

 

Research and Development

 

Research and development expenses consist of salaries and related expenses, share base compensation, consulting fees, related materials and overhead expenses. Research and development expenses for the three months ended March 31, 2022 were $209,362, an increase of $139,571, or 200%, compared to total research and development expenses of $69,791 for the three months ended March 31, 2021. The increase is mainly attributable to an increase in salaries and related expenses and field tests, offset by a decrease in professional fees and share based compensation expenses.

 

Selling and Marketing Expenses

 

Selling and marketing expenses consist primarily of salaries and related expenses for selling and marketing personnel, travel related expenses and services providers and commissions. Selling and marketing expenses for the three months ended March 31, 2022 were $178,136, an increase of $133,878, or 302%, compared to total selling and marketing expenses of $44,258 for the three months ended March 31, 2021. The increase is mainly attributable to the increase in salaries and related costs and professional services.

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries and related expenses including share based compensation and other professional services as well as other non-personnel related expenses such as legal expenses and directors and insurance costs. General and administrative expenses for the three months ended March 31, 2022 were $1,003,957, an increase of $750,986, or 297%, compared to total general and administrative expenses of $252,971 for the three months ended March 31, 2021. The increase is mainly a result of the increase in salaries and related costs, professional services, insurance costs, and share-based compensation to our service providers.

 

Financing Income (Expenses), Net

 

Financing income, net, for the three months ended March 31, 2022 were $5,904, an increase of $253,320, or 102%, compared to total financing expenses of $247,416 for the three months ended March 31, 2021. The increase is mainly a result of decrease in interest and amortization expenses and fair value of our convertible loans related to convertible notes which converted in 2021.

 

18

 

 

Total Comprehensive Loss

 

As a result of the foregoing, our total comprehensive loss for the three months ended March 31, 2022 was $1,339,770, compared to $494,295 for the three months ended March 31, 2021, an increase of $845,475, or 171%. The increase is mainly a result of the increase in research and development expenses, selling and marketing expenses and in general and administrative expenses.

 

Liquidity and Capital Resources

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. Since our inception through March 31, 2022, we have funded our operations, principally with approximately $16 million (net of issuance expenses), from the issuance of shares of our Common Stock, options and loans.

 

On May 13, 2021, we completed an underwritten public offering of 1,090,909 shares of Common Stock at a price to the public of $11.00 per share. The gross proceeds we received from this offering were $12,000,000 (net proceeds of $10,457,862) (the “Underwritten Offering”).

 

The table below presents our cash flows for the periods indicated:

 

   Three Months Ended March 31 
   2022   2021 
Net cash used in operating activities  $(1,087,463)  $(84,548)
           
Net cash provided by (used in) investing activities   (16,342)   4,375 
           
Net cash provided by (used in) financing activities   (2,019)   207,345 
           
Increase (decrease) in cash and cash equivalents  $(1,107,730)  $127,172 

 

As of March 31, 2022, we had cash and cash equivalents of $5,644,466, as compared to $370,072 as of March 31, 2021. As of March 31, 2022, we had a working capital of $5,215,677, as compared to a negative working capital of $202,401 as of March 31, 2021. The increase in our cash balance is mainly attributable to the Underwritten Offering offset by our cash used in operations.

 

Operating Activities

 

Net cash used in operating activities was $1,087,463 for the three months ended March 31, 2022, as compared to $84,548 for the three months ended March 31, 2021. The increase is mainly attributable to our net loss of $1,339,770, partially offset by increases in share based compensation and accounts payable and decrease in other current assets.

 

Investing Activities

 

Net cash used in investing activities was $16,342 for the three months ended March 31, 2022, as compared to net cash provided by investing activities of $4,375 for the three months ended March 31, 2021. The decrease is mainly attributable to the increase in purchase of property and equipment offset by decrease in funds in respect of employee rights upon retirement.

 

Financing Activities

 

Net cash used in financing activities was $2,019 for the three months ended March 31, 2022, as compared to net cash provided by financing activities of $207,345 for the three months ended March 31, 2021. The decrease is mainly the result of decrease in proceeds from convertible loans. 

 

19

 

 

Financial Arrangements

 

During January 2021, we entered into a series of convertible loan agreements with an aggregate principal amount of $274,000 that each bear interest at a rate of 5% per annum.

 

On May 11, 2021 and May 12, 2021, we issued an aggregate of 66,877 shares of Common Stock following the conversion of convertible promissory notes in the aggregate principal amount of $499,000 and of aggregated accrued interest amount of $11,211, at a conversion price of $7.63 per share.

 

On May 18, 2021, we closed the Underwritten Offering pursuant to which we issued a total of 1,090,909 shares of our Common Stock at a purchase price of $11.00 per share. In connection with the Underwritten Offering, we agreed to grant ThinkEquity, a division of Fordham Financial Management, Inc. (the “Underwriter”), a 45-day option to purchase up to 163,636 additional shares of Common Stock at the public offering price of $11.00 per share, less the underwriting discounts and commissions solely to cover over-allotments, and to issue the Underwriter a five-year warrant to purchase up to 54,545 shares of Common Stock, at a per share exercise price equal to 125% of the Underwritten Offering price per share of Common Stock. The gross proceeds from the Underwritten Offering were approximately $12,000,000.

 

Changes to Critical Accounting Policies and Estimates

 

Our critical accounting policies and estimates are set forth in our 2021 Annual Report.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a smaller reporting company, we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our management, including our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2022. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, 2022, our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting or in other factors identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

20

 

 

PART II – OTHER INFORMATION

 

ITEM 1A. RISK FACTORS.

 

Our business faces many risks, a number of which are described under the caption “Risk Factors” in our 2021 Annual Report. Other than as set forth below, there have been no material changes from the risk factors previously disclosed in our 2021 Annual Report. The risks described in our 2021 Annual Report and below may not be the only risks we face. Other risks of which we are not yet aware, or that we currently believe are not material, may also materially and adversely impact our business operations or financial results. If any of the events or circumstances described in the risk factors contained in our 2021 Annual Report or described below occurs, our business, financial condition or results of operations could be adversely impacted and the value of an investment in our securities could decline. Investors and prospective investors should consider the risks described in our 2021 Annual Report and below, and the information contained under the caption “Forward-Looking Statements” and elsewhere in this Quarterly Report on Form 10-Q before deciding whether to invest in our securities.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Except as set forth below, there were no sales of equity securities sold during the period covered by this Quarterly Report on Form 10-Q that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company.

 

On January 27, 2022, the Company issued 12,500 shares of Common Stock under the October 1, 2021 consulting agreement.

 

On March 10, 2022, the Company issued 14,000 shares of Common Stock under the March 10, 2022 investor relations agreement.

 

On March 24, 2022, the Company issued to Mr. Joachim Fuchs, a director of Save Foods Ltd., 9,000 shares Common Stock.

 

The foregoing shares were issued in reliance on the exemptions from registration provided by Section 4(a)(2) under the Securities Act and Regulation D promulgated thereunder for transactions not involving a public offering.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURE

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

21

 

 

ITEM 6. EXHIBITS.

 

(a) The following documents are filed as exhibits to this Quarterly Report or incorporated by reference herein.

 

Exhibit    
Number   Description
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
31.2*   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
32.1**   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document
101.INS*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

*   Filed herewith.
     
**   Furnished herewith.

 

22

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 16, 2022 SAVE FOODS INC.
     
  By: /s/ David Palach
  Name:  David Palach
  Title: Chief Executive Officer
    Save Foods, Inc.

 

  By: /s/ Lital Barda
  Name:  Lital Barda
  Title: Chief Financial Officer
    Save Foods, Inc.

 

23